GENOMICS AND TRANSCRIPTOMICS
Next generation sequencing
With years of experience in genomic analysis, biomarker discovery, and mutation detection, we employ verified, customized manual and automated extraction protocols, along with automated library preparation, to transform your samples into accurate data. Our NGS platforms offer comprehensive sequencing solutions, ranging from small-scale targeted panels to whole genome and transcriptome sequencing, supporting applications from early discovery through to clinical trials.
Nucleic acid experts
NGS service providers since 2015
We manage NGS projects from sample extraction to final data delivery. Our instrument fleet includes multiple Illumina instruments, a Hamilton NGS Star for automated library preparation, and extraction robots. Our strength lies in our flexibility, offering custom workflows based on the number of samples, sample type, and the context of use (COU).
High throughput and comprehensive data
NGS enables the simultaneous sequencing of thousands of genes, entire genomes, total RNA, or all expressed genes, providing deep insights into genetic variations, expression levels, and potential therapeutic targets. It is ideal for both small-scale focused studies and large-scale genomic analyses.
Process automation
Our workflow is nearly fully automated, featuring robots for sample transfer, dilution, extraction, NGS library preparation, and advanced sequencing instruments. This level of automation is essential for managing large sample volumes and ensuring standardized, reliable results.
Scalability and flexibility
NGS can work with small amounts of starting material, such as DNA or RNA from tissue biopsies, FFPE samples, or circulating tumor DNA (ctDNA). Even with small samples, NGS offers high multiplexing capabilities, allowing for scaling from focused panels to whole genomes or transcriptomes.
High sensitivity for heterogenous samples
NGS can detect variants in highly heterogeneous samples, such as tumor biopsies or mixed cell populations, making it invaluable for analyzing tumor heterogeneity and identifying resistance mutations. This capability aids in guiding therapy adjustments and tracking tumor evolution during treatment.
Compatibility with various sample types
NGS can be applied to any biological sample. We extract RNA and DNA from various sample types, carefully assess the quality and integrity of the nucleic acids, and implement multiple control checkpoints during the pre-analytical phase to ensure reliable data.
NGS technologies
NGS is an exciting technology for biomarker profiling in precision medicines and drug product characterization for cell and gene therapies. NGS is a large-scale, rapid, and efficient DNA or RNA sequencing technology.
Next-generation sequencing (NGS) is a powerful technology used to sequence the entire nucleic acid sequence within various biological samples. NGS includes sequencing the complete transcriptome, exome, genome, or specific targeted sequences. Unlike PCR, which requires prior knowledge of the primer and probe design target sequence, NGS strategies can determine the sequence of unknown samples.
In short-read sequencing, we fragment DNA into pieces, add adapters, and then sequence the fragments in parallel on a massive scale. We use computational alignment to assemble the complete transcriptome, exome, or genome. This approach is cost-effective and provides high accuracy compared to traditional Sanger sequencing.
NGS is particularly valuable for transcriptomics, microbiome analysis, and quality assessments. The sequencing depth generates a large number of reads, which not only provides sequencing data but also yields quantitative data. The relative comparison of expressed RNA provides insights into understanding pathway activations, mode of action, target engagement, and potential off-target effects.
NGS is commonly used in biomarker discovery because it can simultaneously analyze multiple genes or transcripts, offering a holistic perspective on the molecular changes linked to a specific disease or treatment. It identifies novel biomarkers, provides insights into the underlying disease mechanisms, and quantifies the biological impacts of therapeutic interventions.
Targeted amplification NGS is employed for identity testing and assessing critical quality attributes (CQAs) in cell and gene therapy products. It enables verification of gene integration sites, determination of gene copy numbers in cell therapy products, and analysis of the potential for insertional mutagenesis, among other applications.
NGS-based biosafety assays offer rapid, accurate, and high-throughput detection of contamination by adventitious agents like bacteria, mycoplasma, and viruses. NGS provides a broader detection range than existing methods, allowing for targeted and untargeted adventitious agent detection.
NGS SERVICES AT TATAA
TATAA Biocenter has years of experience running NGS applications backed by a wide array of NGS instruments for various applications. Our skilled scientists have expertise spanning sample extraction, NGS methodology selection, and execution. Our experienced bioinformaticians excel at the data processing and statistical analysis of intricate NGS data.
Optimization is our priority, with quality control measures implemented at each stage of processing to assess the suitability of samples for library preparation, the quality and quantity of prepared libraries, and confirmation of premium sequencing output.
We tailor our services to match your objectives and requirements, from experimental designs to data analysis. Furthermore, we offer outstanding scalability options, accommodating projects of varying sizes and complexities. Whether you are embarking on small-scale research or large-scale genomics initiatives, we can effectively meet your needs.
Services
Solutions for complex biological challenges
We standardize your custom workflow with a tailed method development. Our approach combines automated, predefined workflows with customized steps, ranging from sample transfer, homogenization, and extraction to downstream applications like NGS library preparation, dilutions, PCR mix preparation, and data interpretation.
compliant bioanalysis
Accurate and reproducible data
A GLP accredited and GCLP compliant laboratory
TATAA Biocenter is accredited by the Swedish Board of Accreditation and Conformity Assessment (SWEDAC) for complying with Good Laboratory Practice (GLP) standards. We also adhere to Good Clinical Laboratory Practice (GCLP) guidelines, which are international quality standards governing the analysis of samples from clinical trials using GLP.
GLP and GCLP validation is mandatory in preclinical and clinical assays to demonstrate accuracy, reliability, and consistency. These standards cover every aspect of study planning, execution, monitoring, documentation, archiving, and reporting. This rigorous process assures both the sponsors, when submitting data for new drug approvals, and the regulatory authorities, when reviewing the data, that it is generated in a regulated manner.
technologies
We operate with the latest technologies
TATAA Biocenter comprises highly skilled scientists with extensive expertise in method development, data analysis, and optimization across diverse technologies. We leverage top-notch instrumentation and automated platforms, offering expert guidance to choose the most suitable technology on the market for your program.
PCR
We use highly sensitive and highly precise quantitative PCR (qPCR) and digital PCR (dPCR) technologies to detect one or multiple DNA/RNA targets in complex samples.
NGS
We use automated, customized workflows tailored to the sample type to simultaneously analyze thousands of genes, whole genomes, and either targeted RNA or full transcriptomes for both small and large-scale studies.
Quantitative proteomics
Olink’s proximity extension assays (PEA) allow multiplexed analysis of hundreds to thousands of proteins using just microliters of blood or plasma, ideal for immune studies and biomarker discovery or validation.
Discovery
Our services in the discovery phase focus on drug target identification and biomarker discovery. We utilize gene expression profiling and genomic analysis to uncover potential drug targets and identify novel biomarkers associated with disease mechanisms. Leveraging advanced technologies such as NGS, qPCR/dPCR, and proteomics, we discover genetic mutations, gene expression patterns, and early-stage biomarkers that can be validated in later phases of development.
Preclinical
In the preclinical phase, our molecular analysis services validate discovered biomarkers and further characterize genomic mutations identified during the discovery phase. We use qPCR, dPCR, and NGS to confirm biomarkers’ accuracy, reproducibility, and clinical relevance. Additionally, our genomic profiling ensures the integrity of cell and gene therapies, identifying potential mutations or safety risks in therapeutic models before progressing to clinical trials.
Clinical
We leverage qPCR, dPCR, and NGS during clinical trials to support patient stratification, monitor drug efficacy, and ensure safety. qPCR and dPCR provide precise mutation detection and gene expression analysis to assess treatment responses in real-time, while NGS enables comprehensive tracking of therapeutic efficacy and the detection of potential adverse effects, optimizing patient outcomes and ensuring clinical success.
Molecular analyses in drug development
Molecular analysis across drug development
We accelerate time-to-market with rapid and reliable data, enabling informed stage-gate decisions and preparing submission-ready reports. We excel at identifying and monitoring nucleic acid biomarkers essential for understanding target engagement, efficacy, potency, and safety of cell, gene, and RNA therapies.
Discovery
Our services in the discovery phase focus on drug target identification and biomarker discovery. We utilize gene expression profiling and genomic analysis to uncover potential drug targets and identify novel biomarkers associated with disease mechanisms. Leveraging advanced technologies such as NGS, qPCR/dPCR, and proteomics, we discover genetic mutations, gene expression patterns, and early-stage biomarkers that can be validated in later phases of development.
Preclinical
In the preclinical phase, our molecular analysis services validate discovered biomarkers and further characterize genomic mutations identified during the discovery phase. We use qPCR, dPCR, and NGS to confirm biomarkers’ accuracy, reproducibility, and clinical relevance. Additionally, our genomic profiling ensures the integrity of cell and gene therapies, identifying potential mutations or safety risks in therapeutic models before progressing to clinical trials.
Clinical
We leverage qPCR, dPCR, and NGS during clinical trials to support patient stratification, monitor drug efficacy, and ensure safety. qPCR and dPCR provide precise mutation detection and gene expression analysis to assess treatment responses in real-time, while NGS enables comprehensive tracking of therapeutic efficacy and the detection of potential adverse effects, optimizing patient outcomes and ensuring clinical success.
Open PDF Controlling and optimizing steps in extracting RNA from PAXgene® blood RNA tubes significantly improves yield and quality and can lead to more accurate preclinical and clinical conclusions. Blood samples are a critical component of clinical trials, and they
Developing new drugs is a complex and multifaceted process that demands precise, targeted approaches to ensure safety, efficacy, and successful regulatory approval. One of the most critical tools in modern drug development is biomarker testing. Biomarkers are measurable indicators that
T-cell cytotoxicity assays A T-cell cytotoxicity assay, also known as a CD8+ T-cell cytotoxicity assay, measures the ability of cytotoxic T lymphocytes to kill target cells. In drug discovery, this assay helps us understand the immune-modulating actions of new therapeutics
why work with tataa?
The power of our approach
Committed to quality, innovation, and fostering strong client relationships, we serve as your trusted partner to accelerate drug development. As a contract research organization, we are committed to generating accurate and reproducible data that shortens time-to-market.
Experienced scientists
We are ahead of industry trends and always updated on the regulatory landscape and requirements for gene editing and nucleic acid-based therapies. Our purpose is to provide data that’s easily auditable.
Total project transparency
We maintain transparency and proactively communicate throughout the project, ensuring our clients always stay updated on the progress. Transparency forms the cornerstone of our proven client model.
Have confidence in your data
We use the highest quality reagents, adhere to dedicated controls, and standardize all processes per technical requirements like the MIQE guidelines. We deliver rapid, robust, and reproducible results that are submission ready.
Flexible and scalable
Every project is customized to meet our client’s specific needs. We manage projects of all sizes and all stages, including any or all phases from sample extraction to analysis and data transfer. Your goals are our deliverables.
contact US
Let's explore how we can support your drug development program
General NGS Page
"*" indicates required fields
